These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10952769)

  • 21. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.
    Ogasawara A; Kume T; Kazama E
    Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
    Masica AL; Mayo G; Wilkinson GR
    Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-throughput approaches to the quantitative analysis of ketoconazole, a potent inhibitor of cytochrome P450 3A4, in human plasma.
    Ramos L; Brignol N; Bakhtiar R; Ray T; Mc Mahon LM; Tse FL
    Rapid Commun Mass Spectrom; 2000; 14(23):2282-93. PubMed ID: 11114039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF.
    Cupp-Vickery JR; Garcia C; Hofacre A; McGee-Estrada K
    J Mol Biol; 2001 Aug; 311(1):101-10. PubMed ID: 11469860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys.
    Ogasawara A; Utoh M; Nii K; Ueda A; Yoshikawa T; Kume T; Fukuzaki K
    Drug Metab Dispos; 2009 Jan; 37(1):122-8. PubMed ID: 18854378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine.
    Hall J; Naranjo CA; Sproule BA; Herrmann N
    J Clin Psychopharmacol; 2003 Aug; 23(4):349-57. PubMed ID: 12920410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam.
    Yuan R; Flockhart DA; Balian JD
    J Clin Pharmacol; 1999 Nov; 39(11):1109-25. PubMed ID: 10579141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: important for the mechanistic understanding of first-pass drug-drug interactions.
    Thörn HA; Hedeland M; Bondesson U; Knutson L; Yasin M; Dickinson P; Lennernäs H
    Drug Metab Dispos; 2009 Nov; 37(11):2186-96. PubMed ID: 19687151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
    Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
    Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
    Yamano K; Yamamoto K; Kotaki H; Sawada Y; Iga T
    Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
    Swart PJ; Krauwinkel WJ; Smulders RA; Smith NN
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):33-6. PubMed ID: 16867168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?
    Ito K; Chiba K; Horikawa M; Ishigami M; Mizuno N; Aoki J; Gotoh Y; Iwatsubo T; Kanamitsu S; Kato M; Kawahara I; Niinuma K; Nishino A; Sato N; Tsukamoto Y; Ueda K; Itoh T; Sugiyama Y
    AAPS PharmSci; 2002; 4(4):E25. PubMed ID: 12645997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of irinotecan metabolism by ketoconazole.
    Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
    J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
    Dresser GK; Spence JD; Bailey DG
    Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FK 506 (Tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs.
    Prasad TN; Stiff DD; Subbotina N; Zemaitis MA; Burckart GJ; Starzl TE; Venkataramanan R
    Res Commun Chem Pathol Pharmacol; 1994 Apr; 84(1):35-46. PubMed ID: 7518966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine.
    Wu CY; Benet LZ; Hebert MF; Gupta SK; Rowland M; Gomez DY; Wacher VJ
    Clin Pharmacol Ther; 1995 Nov; 58(5):492-7. PubMed ID: 7586942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug interactions.
    Med Lett Drugs Ther; 1999 Jul; 41(1056):61-2. PubMed ID: 10436770
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice.
    Fahey JM; Pritchard GA; Moltke LL; Pratt JS; Grassi JM; Shader RI; Greenblatt DJ
    J Pharmacol Exp Ther; 1998 Apr; 285(1):271-6. PubMed ID: 9536021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
    Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.